Research analysts at Burrill Institutional Research cut their target price on shares of Sarepta Therapeutic (NASDAQ: SRPT) Sarepta Therapeutic opened at 30.43 on Friday. Sarepta Therapeutic has a 52-week low of $3.30 and a 52-week high of $45.00. The stock?s 50-day moving average is currently $27.8. The company?s market cap is $774.5 million. Sarepta Therapeutic last issued its quarterly earnings data on Thursday, March 7th. The company reported ($2.36) earnings per share for the quarter, missing the analysts? consensus estimate of ($0.26) by $2.10. The company had revenue of $7.30 million for the quarter, compared to the consensus estimate of $6.71 million. The company?s quarterly revenue was down 46.3% on a year-over-year basis. Analysts expect that Sarepta Therapeutic will post $-1.82 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on SRPT. Analysts at Piper Jaffray reiterated an ?overweight? rating on shares of Sarepta Therapeutic in a research note to investors on Thursday. They now have a $35.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Sarepta Therapeutic in a research note to investors on Tuesday. They set an ?outperform? rating and a $45.00 price target on the stock. Finally, analysts at Cowen initiated coverage on shares of Sarepta Therapeutic in a research note to investors on Friday, January 25th. They set an ?outperform? rating on the stock.
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of both rare and infectious diseases.